[HIV protease inhibitors and interactions].

Area of Science:

• Pharmacology
• Infectious Diseases
• Drug Metabolism

Background:

• Protease inhibitors represent a novel therapeutic class for managing Human Immunodeficiency Virus (HIV) infection.
• These drugs have demonstrated efficacy in decelerating disease progression towards Acquired Immunodeficiency Syndrome (AIDS) and mortality.
• Significant potential for drug-drug interactions exists due to the involvement of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) in their pharmacokinetics.

Purpose of the Study:

• To highlight the therapeutic benefits of protease inhibitors in HIV treatment.
• To elucidate the mechanisms and implications of drug interactions associated with protease inhibitors.
• To discuss strategies for managing and monitoring these interactions.

Main Methods:

• Review of existing literature on protease inhibitor pharmacokinetics and pharmacodynamics.
• Analysis of metabolic pathways involving P-glycoprotein and CYP3A4.
• Discussion of clinical implications of drug-drug interactions.

Main Results:

• Protease inhibitors significantly slow HIV disease progression.
• Co-administration with protease inhibitors can alter concentrations of other drugs, and vice versa.
• Drug interactions can be potentially leveraged by combining specific protease inhibitors.

Conclusions:

• Protease inhibitors offer substantial benefits for HIV-positive patients.
• Understanding and monitoring drug interactions is crucial for optimizing protease inhibitor therapy.
• Plasma concentration monitoring provides a method for managing drug interactions effectively.